Arizona's Meadows Center Adds GLP-1 Drugs to Addiction Care as Studies Probe Craving Cuts
Updated
Updated · Arizona's Family · Jun 12
Arizona's Meadows Center Adds GLP-1 Drugs to Addiction Care as Studies Probe Craving Cuts
2 articles · Updated · Arizona's Family · Jun 12
Summary
The Meadows Behavioral Healthcare Center in Arizona is incorporating GLP-1 peptides into treatment for substance use disorders, extending drugs best known for diabetes and weight loss into addiction recovery.
Dr. Aaron Wilson said emerging research suggests the medications may reduce cravings for alcohol and other substances by acting on the brain’s mesolimbic reward system, a pathway linked to both food cravings and substance use.
Wilson said patients and clinicians are seeing less “noise” not only around food but potentially around alcohol, opiates, stimulants and nicotine, though studies on those effects are still ongoing.
The center is positioning GLP-1s as one tool within a broader treatment plan rather than a standalone fix, urging patients to consult healthcare providers before starting medication.